UCBSTU:UNC -1.93%90 EV-to-FCF is 26.18 as of Jul. 07, 2026, which is 15% above its 10-year median of 22.77. GuruFocus rates STU:UNC with a GF Score™ of 90/100 and a GF Value™ of €211.07 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 329 Biotechnology companies, UCB ranks worse than 62.61% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, UCB's Enterprise Value is €48,226 Mil.
UCB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €1,842 Mil. Therefore, UCB's EV-to-FCF for today is 26.18.
The historical rank and industry rank for UCB's EV-to-FCF or its related term are showing as below:
STU:UNC'
s EV-to-FCF Range Over the Past 10 Years
Min: 8.14 Med: 22.77 Max: 88.96
Current: 26.71
During the past 13 years, the highest EV-to-FCF of UCB was 88.96. The lowest was 8.14. And the median was 22.77.
STU:UNC's EV-to-FCF is ranked worse than 62.61% of 329
companies
in the Biotechnology industry
Industry Median: 16.38
vs STU:UNC: 26.71
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
As of today (2026-07-07), UCB's stock price is €254.30.
UCB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €8.030. Therefore, UCB's PE Ratio (TTM) for today is 31.67.
UCB (STU:UNC) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
UCB's share price for today is €254.30.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. UCB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €8.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
UCB EV-to-FCF Related Terms
UCB EV-to-FCF Historical Data
* Premium members only.
The historical data trend for UCB's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, UCB's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
UCB EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, UCB's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where UCB's EV-to-FCF falls into.
UCB's current Enterprise Value is €48,226 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. UCB's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €1,842 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
UCB (STU:UNC) has a EV-to-FCF of 26.18 as of Jul. 07, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on UCB and its competitors. This is 15% above median its historical median of 22.77. Over the past decade, UCB's EV-to-FCF has ranged from 8.14 to 88.96. According to the industry distribution chart, UCB ranks #206 out of 329 companies in the Biotechnology industry, placing it in the top 62.6%.
Is UCB's EV-to-FCF too high?
UCB's current EV-to-FCF of 26.18 is 15% above median its 10-year median of 22.77. Over the past 10 years, this metric has ranged from a low of 8.14 to a high of 88.96. The Biotechnology industry median EV-to-FCF is 16.38. UCB's value of 26.18 is 59.8% above this industry median. Based on the distribution chart, UCB ranks #206 out of 329 companies in the Biotechnology industry, which is below the industry midpoint. Overall, UCB has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does UCB's EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, UCB ranks #206 out of 329 companies for EV-to-FCF. This places UCB in the lower half of its industry. The industry median EV-to-FCF is 16.38. UCB's value of 26.18 is 59.8% above this benchmark. Historically, UCB's own EV-to-FCF has ranged from 8.14 to 88.96 over the past decade. While the company's 10-year median is 22.77 vs. the industry median of 16.38, UCB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.38, based on 329 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. UCB's current EV-to-FCF of 26.18 is 59.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on UCB and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. UCB's current EV-to-FCF is 26.18, which is 15% above median its own 10-year median of 22.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is UCB stock overvalued right now?
Based on GuruFocus' analysis, UCB (STU:UNC) is currently considered Modestly Overvalued. The stock's GF Value™ is €211.07, compared to a current price of €254.30 — trading 20.5% above its estimated fair value. The current EV-to-FCF is 26.18, which is 15% above median its 10-year median of 22.77 and 59.8% above the Biotechnology industry median of 16.38. UCB's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For UCB (STU:UNC), the current EV-to-FCF is 26.18 as of Jul. 07, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is UCB (STU:UNC) Overvalued in 2026?
Based on GuruFocus' analysis, UCB stock appears to be overvalued.
The current stock price of €254.30 is trading 20.5% above its estimated GF Value™ of €211.07.
GuruFocus considers UCB to be Modestly Overvalued.
Key valuation signals for STU:UNC:
EV-to-FCF: 26.18 (15% above median its 10-year median of 22.77)
GF Value™: €211.07 vs. price of €254.30 (20.5% above fair value)
Industry Position: 59.8% above the Biotechnology median (#206 of 329)
No single metric tells the full story. See the STU:UNC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which have both lost patent protection. The firm's key products are Cimzia (immunology), Vimpat (epilepsy), Neupro (Parkinson's disease and restless leg syndrome), Briviact (epilepsy), Bimzelx (psoriasis), Evenity (osteoporosis), Nayzilam (cluster seizures), Fintepla (Dravet Syndrome and Lennox-Gastaut Syndrome), and Kygevvi (rare mitochondrial disease).
90GF Score
Get the complete analysis for STU:UNC
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:UNC has been successfully added to your 
